Commack: 
Regeneron
New Treatment for Diabetic Macular Edema
Enrollment is Open
About this Study
A randomized, double-masked, active-controlled phase 2/3 study of the efficacy and safety of high-dose aflibercept in patients with diabetic macular edema.
This study is using a higher concentration of Eylea with the hope that patients will need injections much less frequently, hopefully, every 3-4 months and still maintain visual improvements.
Genentech Lucerne Study
Enrollment is Closed
This is a new drug called faricimab that may allow us to dose less frequently for wet AMD
BEOVU
HAWK Study
About this Study
The purpose of this study was to compare RTH258 ophthalmic solution for intravitreal (IVT) injection at two dosage levels to aflibercept solution for IVT injection (2 mg) in subjects with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye.
New Treatment for Neovascular Age-Related Macular Degeneration
Study is now closed
About this Study
This is a phase 3 study using Combercept which is a long- acting antiVEGF agent.
It is hoped that with this drug, patients will require fewer eye injections.
Genentech Yosemite Study
New Treatment for Diabetic Macular Edema
Study is now closed
About this Study
This is a phase 3 study looking at a new drug RO6867461. It has the potential to improve vision with fewer eye injections.